Anne Bass is a Rheumatology/Immunology physician affiliated with Hospital for Special Surgery. OpenAlex indexes 173 publications with 3,823 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Pilot Study of Atorvastatin for Orthopedic Surgery Patients
Sponsor: Hospital for Special Surgery, New York
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.5%Corticosteroid32.7%Prednisone100%Part D≥78 patientsAntidiarrheal microorganisms2.5%Folic Acid100%Part D≥12 patients+ 2 more classes in this area
Cancer & immunology
25%Folate Analog Metabolic Inhibitor14.4%Methotrexate100%Part D≥43 patientsTNF inhibitor3.9%Humira(Cf) Pen37%Simponi34%Enbrel29%Part D<11 patients+ 5 more classes in this area
Antiparasitic
12.6%Antimalarial12.6%Hydroxychloroquine Sulfate100%Part D≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety
Hospital for Special Surgery
FY2025$267,423R01AR085258
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lockshin, MD
Hospital for Special Surgery
Lionel Ivashkiv, MD
Hospital for Special Surgery
Vivian Bykerk, VIVIAN, BYKERK, MD
Hospital for Special Surgery
Jane Salmon, MD
Hospital for Special Surgery
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”